Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
Open accessThe DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
If tuberculosis (TB) is to be eliminated as a global health problem in the foreseeable future, improved detection of patients, earlier diagnosis and timely identification of rifampicin resistance will be critical. New diagnostics released in recent years have improved this perspective but they require investments in laboratory infrastructure, biosafety and staff specialisation beyond the means of many resource-constrained settings where most patients live. Xpert MTB/RIF, a new assay employing automated nucleic acid amplification to detect Mycobacterium tuberculosis , as well as mutations that confer rifampicin resistance, holds the promise to largely overcome these operational challenges. In this article we position Xpert MTB/RIF in today’s TB diagnostic landscape and describe its additional potential as an adjunct to surveillance and surveys, taking into account considerations of pricing and ethics. In what could serve as a model for the future formulation of new policy on diagnostics, we trace the unique process by which the World Health Organization consulted international expertise and systematically assessed published evidence and freshly emerging experience from the field ahead of its endorsement of the Xpert MTB/RIF technology in 2010, summarise subsequent research findings and guidance on who to test and how, and provide perspectives on scaling up the new technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIGURE 2 The step-by-step Xpert MTB/RIF assay process. SR: sterilising reagent. Reproduced from [6] with permission from the publisher.](https://figures.cochat.ai/paper-figures/98f7479eb2a54ba68e155f0517fcac34/rapid-molecular-tb-diagnosis-evidence-policy-making-and-global-implementation-of-figure-2.png)

![FIGURE 4 Global uptake of Xpert MTB/RIF up to June 30, 2012. As of June 30, 2012, a total of 749 GeneXpert instruments (comprising 3602 modules) and 1107330 Xpert MTB/ RIF cartridges had been procured in the public sector in 67 of the 145 countries eligible for concessional pricing. Reproduced from [6] with permission from the publisher.](https://figures.cochat.ai/paper-figures/4789cae0ecc24836a2aa7c4f09135c32/rapid-molecular-tb-diagnosis-evidence-policy-making-and-global-implementation-of-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Quantifying the burden of disease: the technical basis for disability-adjusted life years.
Murray, C. J. L. (1994) · Europe PMC (PubMed Central) · Cited by 1,581
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Self-citationSelective Primary Health Care: An Interim Strategy for Disease Control in Developing Countries
Walsh, J. A., & Warren, K. S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197911013011804 · Cited by 1,034
Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Infections and inequalities: the modern plagues
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3356 · Cited by 958
Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Tuberculosis in New York City — Turning the Tide
Frieden, T. R., Fujiwara, P. I., Washko, R. M., & Hamburg, M. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330406 · Cited by 640
Research works printed but not linked: 1
- 10.1016/S0140-6736(11)61242-7 · DOI
Cited by
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Walker, T. M., Kohl, T. A., Omar, S. V., Hedge, J., Del Ojo Elias, C., Bradley, P., Iqbal, Z., Feuerriegel, S., Niehaus, K. E., Wilson, D. J., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00062-6 · Cited by 638
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527
Point-of-Care Diagnostics: Recent Developments in a Connected Age
Nayak, S., Blumenfeld, N. R., Laksanasopin, T., & Sia, S. K. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04630 · Cited by 508
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Metadata
- Authors
- Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., Gilpin, C., de Dieu Iragena, J., Falzon, D., & Raviglione, M.
- Affiliations
- World Health Organization (CH)
- Fondazione Salvatore Maugeri (IT)
- IRCCS San Raffaele Roma (IT)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2012-11-22
- Volume
- 42
- Issue
- 1
- Pages
- 252-271
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2132406189
- Cited by
- 256
- References
- 137
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 14 · 2023: 6 · 2022: 5 · 2021: 16 · 2020: 10 · 2019: 21 · 2018: 17 · 2017: 25 · 2016: 28 · 2015: 33 · 2014: 40 · 2013: 30
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Keywords
- Xpert MTB/RIF, tuberculosis diagnosis, rifampicin resistance, Mycobacterium tuberculosis, tuberculosis elimination, resource-limited settings, tuberculosis surveillance, rapid molecular diagnostics
- MeSH terms
- Cost-Benefit Analysis, Drug Resistance, Health Policy, Humans, Mycobacterium tuberculosis, Predictive Value of Tests, Sputum, Tuberculosis, Pulmonary, World Health Organization, Reproducibility of Results, Prevalence, Polymerase Chain Reaction, Tuberculosis, Multidrug-Resistant, Nucleic Acid Amplification Techniques, Molecular Diagnostic Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. https://app.cochat.ai/papers/10.1183/09031936.00157212
- The paper
- Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., Gilpin, C., de Dieu Iragena, J., Falzon, D., & Raviglione, M. (2013). Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal. https://doi.org/10.1183/09031936.00157212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.